Ekso Bionics Stock Price, News & Analysis

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the completion of its public offering, closing 3,902,440 shares of common stock at $10.25 each. The offering generated approximately $40 million in gross proceeds, with a 30-day option for underwriters to purchase an additional 585,366 shares. The proceeds will be allocated towards working capital, debt repayment, acquisitions, and other corporate purposes. This offering was managed by H.C. Wainwright & Co. The shares were issued under a previously filed registration statement with the SEC.

Ekso Bionics has announced an increase in its public offering to 3,902,440 shares at $10.25 each, aiming to raise approximately $40 million before expenses. The offering, managed by H.C. Wainwright & Co., is set to close around February 11, 2021. Additionally, an option for the underwriter to purchase 585,366 more shares is included. The funds will be used for working capital, debt repayment, and other corporate purposes, indicating the company's intention for growth and strengthening its financial position.

Ekso Bionics has announced a firm commitment underwriting agreement with H.C. Wainwright & Co. to purchase 975,610 shares of common stock at $10.25 each, aiming to raise approximately $10 million. This offering is expected to close on February 11, 2021. Additionally, the underwriter has a 30-day option to buy another 146,341 shares. The proceeds will be used for working capital, debt repayment, and potential acquisitions. The offering is registered under Form S-3 with the SEC.

Ekso Bionics (Nasdaq: EKSO) announced preliminary financial results for Q4 and FY 2020, with Q4 revenue estimated at $2.3 million, down from $3.7 million in Q4 2019. Total revenue for FY 2020 is about $8.9 million, compared to $13.9 million in 2019. Cash reserves rose to $12.9 million from $10.9 million year-over-year. CEO Jack Peurach highlighted strong performance despite COVID-19 challenges and a new subscription model aimed to expand their market. The company plans to report complete results in late February 2021.

Ekso Bionics (Nasdaq: EKSO) announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2021. Jack Peurach, CEO, and Jack Glenn, CFO, will present at this event. An on-demand company presentation will be available starting January 11 at 6:00 AM ET on the company's website. Ekso Bionics specializes in exoskeleton technology aimed at enhancing strength and mobility for medical and industrial applications, furthering its mission to amplify human potential.

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced the election of Mary Ann Cloyd and Rhonda A. Wallen to its Board of Directors, effective December 29, 2020. Both directors bring extensive experience in business and healthcare. Cloyd has nearly 40 years of experience in public accounting and corporate governance, while Wallen has 25 years in life sciences and healthcare. Their insights are expected to enhance corporate strategy and value for stockholders as Ekso Bionics continues advancing its exoskeleton technology for medical and industrial applications.

Ekso Bionics Holdings (Nasdaq: EKSO) has announced a subscription-based order for its EVO exoskeleton from Cloverdale Foods Company, a family-owned meat company. This adoption highlights the effectiveness of EVO in reducing worker fatigue and enhancing productivity in the food processing sector. Cloverdale plans to implement the EVO Exoskeleton Program to ensure employee safety while meeting increased product demand. The EVO exoskeleton features a customized fit, reduced weight, and is rigorously tested for quality, aiming to enhance workplace efficiency and employee health.

Ekso Bionics (Nasdaq: EKSO) announced its Q3 financial results for 2020, reporting revenues of $2.9 million, a sequential increase from $2.3 million in Q2. Gross margins improved to 63% versus 53% a year earlier, attributed to higher selling prices and reduced production costs. Cash reserves stood at $14.5 million, bolstered by $2.5 million from warrant exercises. However, overall revenue decreased compared to last year due to COVID-19 impacts on sales. Despite challenges, the company launched the EVO exoskeleton, which received positive initial interest.

Ekso Bionics (Nasdaq: EKSO) has launched its innovative EVO exoskeleton, aimed at reducing fatigue-related injuries among industrial workers. EGM Builders is the first customer to adopt this technology, which offers lift assistance to alleviate physical strain during overhead tasks. The EVO device enhances worker safety and productivity, aligning with EGM Builders' commitment to employee well-being. Despite the promising features, the company faces potential risks, including market acceptance and competition, as indicated in their forward-looking statements.